Extract
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB [1]. The World Health Organization (WHO) estimates that one-third of the global population is infected by Mycobacterium tuberculosis [2]. They cannot transmit tuberculosis (TB), but they can develop the disease and become infectious with a life-time risk of approximately 5–15% [3]. A significant proportion of new TB patients, especially in low burden countries, are presumed to occur from the pool of individuals with LTBI.
Abstract
LTBI treatment: a systematic review on the best clinical approach to monitor the adverse events of preventive therapy http://ow.ly/HyjAH
Footnotes
Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com
- Received November 24, 2014.
- Accepted December 16, 2014.
- The content of this work is ©the authors or their employers. Design and branding are ©ERS 2015.
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. This article is one of a selection of articles published as ERJ Open papers, as part of an initiative agreed between the European Respiratory Society and the World Health Organization.